BMS racks up Opdivo combo data to sell its new biomarker by Carly Helfand Monday, June 4, 2018 Bristol-Myers Squibb has new data to support the notion that its new biomarker can help predict who can best benefit from I-O combos.
BMS gets Opdivo into FDA fast lane for new melanoma use by Tracy Staton Wednesday, October 18, 2017 Bristol-Myers aims to get its I-O med Opdivo to cancer patients as early as possible, and a new approval in melanoma would be a step in that direction.
